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Background: Ankylosing enthesopathy (ANKENT) is an animal model of human ankylosing spondylitis. ANKENT is
an inflammatory disease affecting the ankle and tarsal joints of the hind limbs in susceptible mouse strains. In the
disease, the participation of intestinal microbiota components was suggested. Therefore, we attempted to increase
the incidence of ANKENT by systemic administration of lipopolysaccharide (LPS), which is a component of bacterial
cellular walls and stimulates inflammatory processes.
Methods: ANKENT occurrence, serum cytokine profiles, spleen cellular composition and in vitro cytokine response
to LPS were analysed in LPS-treated and control LPS-untreated B10.BR male mice.
Results: Contrary to expectations, LPS treatment decreased the incidence of ANKENT in LPS-treated group
compared to control LPS-untreated group. Flow cytometry analysis of splenocytes showed an increased percentage
of macrophages, dendritic cells and neutrophils and a decreased percentage of B cells, T cells and T helper cells in
LPS-treated males following LPS administration. In addition, LPS-treated males had significantly elevated IL-6 and
IL-10 serum levels. At 20–22 weeks after the final LPS application, splenocytes from LPS-treated mice were more
susceptible to in vitro LPS stimulation than those of the controls and produced significantly higher levels of TNFα
and IL-6.
Conclusions: Repeated systemic stimulation with microbial component lipopolysaccharide in early adulthood
significantly reduced the incidence of ANKENT in B10.BR mice and this finding can support the “hygiene
hypothesis”. In LPS-treated mice, the innate immunity parameters and the level of anti-inflammatory IL-10 cytokine
were significantly increased. Nevertheless, the immunological mechanism of the LPS protective effect remains
unclear.Background
Ankylosing spondylitis (AS) is a serious rheumatological
disease resulting in patient disability. The disease affects
mainly men and the first symptoms usually manifest
themselves in early adulthood. A relevant genetic risk
factor for AS is the HLA-B27 allele: 96% of AS patients
carry the HLA-B27 gene [1,2]. To study the causes of
AS, various biological models were created [3-6].* Correspondence: tomas@gnotolab.com
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reproduction in any medium, provided the orOur animal model for AS shows disease of the ankle
and tarsal joints in the hind paws of mice. The disease
affects joints and entheses, which are the areas of inser-
tion of ligaments, tendons or joint capsules into bone.
Analogously to human spondyloarthropathies (SpA)
[7,8], enthesitis is a specific marker of the affected joints
and the disease was classified as ankylosing enthesopa-
thy (ANKENT) [9]. The disease occurs spontaneously in
some inbred mouse strains [10,11] and almost exclu-
sively in males [12]. Its incidence is significantly
increased in HLA-B27 mice [11], confirming an implica-
tion of the B27 allele in ANKENT development.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2474/13/110The disadvantage of the ANKENT model is the rela-
tive low frequency of the disease - about 10% B10.BR
male mice under conventional (CV) and about 5% mice
under specific pathogen free (SPF) conditions naturally
develop ANKENT [11].
In previous studies, we found that germ-free mice re-
main ANKENT free [13] and their colonization with a
mixture containing a low number of common intestinal
bacteria (Bacteroides sp., Enterococcus sp., Staphylococ-
cus sp., Veillonella sp.) alone results in ANKENT devel-
opment [14]. Because mucosal barrier impairment and
the consequent increased penetration of commensal
microbiota components were suggested to play a role in
the disease development [15], we attempted to induce
ANKENT and increase its frequency through the sys-
temic administration of lipopolysaccharide (LPS). LPS, a
component of bacterial cellular walls, is an efficient
stimulator of the immune inflammatory response [16]
and its intraperitoneal application increases intestinal
permeability [17]. A further aim of our work was to
study the immunological profile of ANKENT-susceptible
B10.BR mice during LPS administration and at the end




ANKENT- susceptible inbred B10.BR (C57BL/10 genetic
background, H-2k haplotype) male mice born to females
at the age of 2 ½ - 3 months were used in the experi-
ments. The litters were split before sexual maturity and
males from each litter were divided into two groups:
LPS-treated and control LPS-untreated (PBS-treated)
group. In the experiment there were 73 LPS-treated
males and 88 LPS-untreated control males. In the course
of LPS administration, after the second and the fourth
LPS dose, and at the end of the experiment, i.e. 20–
22 weeks after the fourth LPS dose, always 9 LPS-
treated and 9 control males were sacrificed and sera and
spleens collected (Figure 1). All mice were housed under
the same conventional conditions, fed the same diet and
caged 4–6 males together.
All experiments were approved by the Institutional
Animal Care Committees of the Institute of Biotechnol-
ogy and the Institute of Microbiology and were in ac-
cordance with the EC Directive 86/609 EEC for animal
experiments.
ANKENT screening and evaluation
ANKENT is a progressive stiffening of the ankle and tar-
sal joints in the hind paws of mice. Joint stiffness was
evaluated by gentle stretching once a week and a score
between 0 (normal mobility) and 3 (completely immo-
bile) was assigned. Scores of 2 and above were regardedas clearly positive for ANKENT. Joints of some ANK-
ENT positive animals were also checked by radiography.
The mice were observed until they reached the age of
10 months.
LPS and its administration
LPS was isolated from E. coli O83 and purified by
phenol-water extraction [18]. Twenty mg of LPS was
dissolved in 20 ml of sterile PBS and the solution was
administered immediately or aliquoted and stored at –
20 °C until used. Mice were intraperitoneally (i.p.)
injected with LPS (100 μg LPS/0.1 ml PBS per mouse)
four times at two-week intervals. At the beginning of
LPS treatment the males were 3-31/2months old. Con-
trol LPS-untreated mice were injected i.p. with 0.1 ml
PBS according to the same schedule.
Antibodies
The following monoclonal antibodies with matching iso-
type controls were used: PE-conjugated anti-mouse
CD19 for detection of B cells; FITC-conjugated anti-
mouse CD3e, FITC-conjugated anti-mouse CD4, PE-
conjugated anti-mouse CD8a and PE-conjugated anti-
mouse Foxp3 for detection of T cells and their subpopu-
lations; PE-conjugated anti-mouse CD49b for detection
of NK cells; PE-conjugated anti-mouse CD11b, FITC-
conjugated anti-mouse CD11c, and PE-Cy5 conjugated
anti-mouse Ly-6 G for detection of leukocyte popula-
tions. All monoclonal antibodies were purchased from
eBioscience, USA.
Flow cytometry
Phenotypic analysis of cells isolated from the spleen was
performed using flow cytometry (FACS). Cells were
resuspended in ice-cold FACS buffer (1% bovine serum
albumin and 0.1% sodium azide in PBS) to a concentra-
tion of 2 x 107 cells/ml and pre-incubated with 1 μg of
anti-mouse CD16/CD32 per 106 cells for 5 min on ice
prior to staining. Antibodies were diluted to predeter-
mined optimal concentrations in 50 μl of FACS buffer
and dispensed into wells of a 96-well microtiter plate.
Fifty μl of the cell suspension was added to each well
and incubated for 20 min at 4 °C in darkness. Then, the
cells were washed twice and resuspended in 100 μl of
FACS buffer. Intracellular staining of mouse Foxp3 was
performed using PE anti-mouse Foxp3 Staining Set
according to the manufacturer’s protocol. Sample data
were acquired using FACSCalibur flow cytometer (Bec-
ton Dickinson, USA) and analysed with FlowJo software
(Tree Star, USA).
Serum samples
Blood samples were collected the third day after the sec-
ond and the fourth LPS dose and at the end of
Figure 1 ANKENT occurrence and LPS administrations. LPS or PBS was administered i.p. to B10.BR males from the age of 3–3.5 months in
two-weeks intervals (four times). The ANKENT occurrence was recorded throughout the whole experiment. The incidence of ANKENT was
significantly lower in the LPS-treated group (1/55) compared to control PBS group (10/70; Fisher’s exact test p< 0.02). To analyze immune
parameters sera and spleens were collected three days after the second and the fourth LPS dose and at the end of experiment (3x9 mice of each
group).
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for 2 h at room temperature, centrifuged and sera were
collected and stored at −20 °C until cytokine analysis.
In vitro cytokine stimulation
Spleen cells were cultured at 2 x 106 cells/ml in a 96-
well flat-bottom culture plate in complete RPMI-1640
medium. The cells were stimulated with 10 μg/ml LPS
and incubated in 5% CO2 at 37 °C for 48 h.
Multiplex cytokine determination
Cytokine levels in sera and supernatants were detected
using fluorescent beads coated with analyte-specific cap-
ture antibodies (BioSource, USA) according to the man-
ufacturer’s protocols. The beads were analyzed using the
Bio-Plex System (Bio-Rad Laboratories, Hercules, USA).
Statistical analysis
Statistical differences in ANKENT occurrence between
LPS-treated and control groups were evaluated by Fish-
er’s exact test (two-tailed). P values less than 0.05 were
considered statistically significant.
Data concerning the proportional representation of
cell populations and cytokine levels are expressed as
mean ± standard deviation (SD). Statistical differencesbetween LPS-treated and control groups were examined
using the Student’s t test. A p-value of <0.05 was consid-
ered statistically significant. Statistical significance was
analyzed using Prism 5.0 statistical software (GraphPad
Software, San Diego, CA).Results
ANKENT occurrence
ANKENT occurs particularly in inbred mouse strains
with the C57BL genetic background. The disease begins
with mild swelling and redness in the ankle area and in
a short period of time (2–4 weeks) culminates in irre-
versible stiffening of the ankle and tarsal joints (Figure 2).
Proliferative inflammation of the joints and adjacent tis-
sues causes ossification of the joint cartilage [10] which
is well seen on a radiograph (Figure 3).
Among LPS-treated males we found only one ANK-
ENT positive male, i.e. 1.8% (1/55) incidence. On the
other hand, ANKENT occurrence in the control LPS-
untreated males was relatively high and joint disease
developed in 14.2% (10/70) cases (Figure 1). Statistical
evaluation by Fisher’s exact test demonstrated a signifi-
cant difference in ANKENT incidence between LPS-
treated and control males (p< 0.02).
Figure 2 ANKENT in both paws. A 7-month-old ANKENT-positive
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http://www.biomedcentral.com/1471-2474/13/110Leukocyte subpopulations in the spleen
FACS analysis of spleen cells showed that LPS stimula-
tion affected the proportion of macrophages (CD11b+),
dendritic cells (CD11c+) and neutrophils (Ly-6G+) in
the spleen (Figure 4). After the second LPS dose, LPS-
treated males had a significantly higher percentage of
CD11b+, CD11c + and Ly-6G+ leukocytes (p< 0.01)
compared to control LPS-untreated males (Figure 4A).
The increased percentage of CD11b+ and Ly-6G+ cells
(p< 0.01) also persisted after the fourth LPS dose
(Figure 4B). However, at the end of the experiment both
LPS-treated and control males had almost identical pro-
portions of leukocyte subpopulations (Figure 4C) and no
statistical differences were found between the LPS-
treated and the control group.
Lymphocyte subpopulations in the spleen
Significant differences in lymphocyte subpopulations in
the spleen were observed between LPS-treated and con-
trol LPS-untreated males through the course of LPSFigure 3 A radiograph of ANKENT-positive male. A control
LPS-untreated male with the right paw affected. The left paw is normal.
Figure 4 FACS analysis of leukocyte subpopulations in the
spleens of LPS-treated and control LPS-untreated B10.BR
males. After the second LPS dose the percentage of macrophages
(CD11b+), dendritic cells (CD11c+) and neutrophils (Ly-6G+) was
increased in LPS-treated males (A) and the increase of CD11b+ and
Ly-6G+ cells lasted after the fourth LPS dose (B). No significant
differences in the percentage of CD11b+, CD11c+ and Ly-G6+ cells
were found between both groups 20–22 weeks after the fourth LPS
dose (C). * p< 0.05, ** p< 0.01.administration (Figure 5). FACS analysis of splenocytes
demonstrated a decreased percentage of CD19+ B cells
(p< 0.05), CD3+ T cells (p< 0.01) and CD4+ T helper
cells (p< 0.01) after the second LPS dose (Figure 5A).
The decrease in percentage of CD19+ B cells (p< 0.01)
persisted and even deepened after the fourth LPS dose
(Figure 5B). The percentage of CD8+, CD4+Foxp3+ and

































































































































Figure 5 FACS analysis of lymphocyte subpopulations in the
spleens of LPS-treated and control LPS-untreated B10.BR
males. A decreased percentage of B cells (CD19+) and an increased
percentage of natural killer cells (CD3-CD49b+) after the second
and the fourth LPS dose (A, B) and a decreased percentage of
T cells (CD3+, CD4+) after the second LPS dose (A) were found in
LPS-treated males. No differences in the percentage of B cells
(CD19+), subpopulations of T cells (CD3+, CD8+, CD4+, and
CD4+Foxp3+) and natural killer cells (CD3+CD49b+, CD3-CD49b+)
were found between both groups 20–22 weeks after the fourth LPS
dose (C). * p< 0.05, ** p< 0.01.
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http://www.biomedcentral.com/1471-2474/13/110treatment (Figure 5A, B). The proportion of CD3-
CD49b+ natural killer cells was increased in LPS-treated
males compared to control males (p< 0.05 resp. p< 0.01)
(Figure 5A, B). At the end of the observation period the
expression of B cells (CD19+), T cells (CD3+), cytotoxic
T cells (CD8+), helper T cells (CD4+), and regulatory
T cells (CD4+Foxp3+) as well as natural killers (CD3-
CD49b+) and natural killer T cells (CD3+CD49b+)
was comparable and nearly identical in both groups
(Figure 5C).
Cytokine levels in blood sera
The following cytokines were measured: TNFα, IL-6,
IFNγ, TGFβ, and IL-10. After the second and the fourth
LPS dose there were significantly elevated levels of IL-6
(p< 0.01) and IL-10 (p< 0.01) (Figure 6A, B). At the
end of the experiment the levels of TNFα, IL-6, and
IFNγ cytokines were not significantly different between
the LPS-treated and the control group and the levels of
TGFβ and IL-10 cytokines were bellow the detection
limit of the method (Figure 6C). However, IL-6 and
TNFα were elevated in both LPS-treated and PBS-
treated control groups (Figure 6C).
In vitro cytokine response of spleen cells
Spleen cells from LPS-treated and control males were
stimulated in vitro with LPS and the levels of TNFα,
IL-6, IFNγ, TGFβ and IL-10 in cell supernatants were
evaluated (Figure 7). After the fourth LPS dose the
IL-6 level was significantly higher in LPS-treated males
(p< 0.05) than in the controls (Figure 7B). Twenty-two
weeks after the final LPS dose the splenocytes isolated
from LPS-treated males were more susceptible to LPS
stimulation and produced significantly higher levels of
pro-inflammatory cytokines TNFα (p< 0.01) and IL-6
(p< 0.05) than splenocytes from LPS-untreated control
males (Figure 7C).
Discussion
Bacterial lipopolysaccharide (endotoxin) triggers acute
inflammation, associated with activation of the innate
immune system and production of multiple proinflam-
matory mediators [19,20]. In this study, we attempted to
utilize the proinflammatory capability of LPS to enhance
the incidence of the naturally occurring inflammatory
joint disease ANKENT in mice.
ANKENT develops almost exclusively in males and
this hallmark of the disease is associated with hormonal
and behavioural factors – similarly as in naturally occur-
ring arthritis in DBA/1 male mice [21]. The males caged
together have a significantly higher risk of ANKENT de-
velopment than males caged alone [22]. During the
whole experiment both LPS-treated and LPS-untreated
males were caged under the same conditions and we







































Figure 6 Cytokine levels in blood sera of LPS-treated and
control LPS-untreated B10.BR males. Values of TNFα, IL-6, IFNγ,
TGFβ and IL-10 represent the mean ± SD. IL-6 and IL-10 were
significantly increased in LPS-treated males after the second and the
fourth LPS dose, TNFα after the fourth LPS dose (A, B). No significant
differences in cytokine levels were found at the end of the
experiment, i.e. 20–22 weeks after the fourth LPS dose (C). TGFβ and
in some cases IFNγ and IL-10 were under the limit of the detection
kit. * p< 0.05, ** p< 0.01.


































Figure 7 In vitro cytokine response of splenocytes from
LPS-treated and control LPS-untreated B10.BR males to LPS
stimulation. TNFα, IL-6, IFNγ, TGFβ and IL-10 in cell supernatants
were determined. No significant differences were found between
LPS-treated males and the control group after the second LPS
dose (A). After the fourth LPS dose the IL-6 level was significantly
increased in LPS-treated males (B). At the end of the experiment
splenocytes from LPS-treated males responded to LPS stimulation
by significantly higher production of TNFα and IL-6 cytokines (C).
* p< 0.05, ** p< 0.01.
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between the groups.
Previously, we showed that germ-free mice do not suf-
fer from the joint disease [13]. However, after their
colonization with a mixture containing common intes-
tinal bacteria, some mice developed ANKENT [14]. The
close connection between the gut and SpA was repeat-
edly demonstrated in laboratory animals [23-27] and
was also confirmed in humans [28-33]. Because LPS is
an agent which when administered intraperitoneally
enhances intestinal permeability, and leads to transloca-
tion of commensal microbiota from the gut [17], we
expected a higher frequency of the disease in LPS-treated males. Surprisingly, LPS administration to
ANKENT-susceptible B10.BR male mice in their early
adulthood acted protectively: the incidence of ANKENT
in LPS-treated males was significantly reduced compared
to control LPS-untreated group. This unexpected result
could be explained by an overactivation of innate im-
munity cells leading to an upregulation of negative regu-
latory pathways [34].
The second aim of our work was to study the immune
response. The cellular infiltrate in joints and elevated IL-
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positive animals at the time when ANKENT became
manifest [9,11]. These signs disappeared after the period
of acute inflammation. In this study we did not test mice
in the acute stages of the disease, but we were interested
in the immune response that precedes ANKENT onset.
We compared populations of immune cells and cytokine
levels in LPS-treated group, where ANKENT occurrence
was suppressed, with the control LPS-untreated group,
where ANKENT was manifest.
Throughout the course of LPS administration, signifi-
cantly higher percentages of macrophages (CD11b+),
dendritic cells (CD11c+), neutrophils (Ly6G+) and also
natural killer cells (CD3-CD49b+) were found in LPS-
treated males than in LPS-untreated ones. This LPS-
induced expansion of innate immune cells in spleen was
transient and was not present at the end of experiment
when the frequencies of these populations were similar
in both groups.
Just the opposite effect of LPS treatment was observed
in lymphocyte subpopulations. During LPS administra-
tion the percentage of B cells, T cells and T helper cells
in the spleen was significantly decreased in LPS-treated
males and the decrease in frequency of B cells lasted
throughout LPS treatment. At the end of the experi-
ment, no differences were found between LPS-treated
and LPS-untreated males. This suggests that cells of the
adaptive immune system did not directly participate in
the immune response to LPS treatment, and the sup-
pression of adaptive immunity in LPS-treated males
might be involved in the reduction of ANKENT
incidence.
Specific cells of innate and adaptive immunity are
associated with the production of cytokines. In LPS-
treated males we found significantly increased serum
levels of IL-6 and IL-10 during LPS administration,
whereas the percentage of CD4+ T cells, which is an im-
portant source of these cytokines, was decreased. How-
ever, macrophages also produce IL-6 and monocytes,
whose frequency was strongly elevated in LPS-treated
males, are the main cellular source of IL-10.
The finding of significantly elevated IL-10 levels in
sera of LPS treated males was discrepant with the
in vitro response of LPS stimulated splenocytes, which
did not secrete detectable IL-10. This contradiction be-
tween serum and in vitro spleen cell response to LPS
stimulation could be explained by the fact that the
major source of circulating IL-10 after LPS stimulation
is liver [35].
No significant serum differences were found between
LPS-treated and LPS-untreated males in IL-6 and IL-10
and in all other tested cytokines at the end of the experi-
ment. However, IL-6 and TNFα were elevated in both
groups. The elevation of these pro-inflammatory cytokinesat the end of experiment could be explained by the pres-
ence of ANKENT-positive animals. We could only specu-
late that LPS treatment suppressed and delayed the onset
of ANKENT and that cytokine data both from serum and
from in vitro stimulation show the subclinical signs of dis-
ease. Nevertheless, at the end of the experiment we have
detected only a single affected mouse in LPS-treated
group. To evaluate the data in more detail we would need
to match single cytokine data with individual mice. How-
ever, both LPS-treated as well as LPS-untreated control
males were evaluated as a group.
We do not know the exact mechanism of LPS effect in
ANKENT development, but the high level of anti-
inflammatory cytokine IL-10 could contribute to homeo-
stasis in LPS-treated males. IL-10, which is a potent
anti-inflammatory agent, might suppress the onset of
ANKENT by its effect on the secretion of pro-
inflammatory cytokines including TNFα and IL-6. A
regulation of IL-10 is connected with a function of pro-
inflammatory TNFα. In mice, TNFα up-regulates LPS-
induced IL-10 synthesis and neutralization of TNFα with
anti TNFα antibody results in a significant reduction of
LPS-inducible IL-10 production [35].
To better understand the immune mechanisms under-
lying the development of ANKENT, in vitro LPS stimu-
lation of splenocytes was performed. In the course of
LPS administration we observed an elevated level of IL-6
in supernatants of splenocytes from LPS-treated males.
This result was consistent with the elevated IL-6 levels
in blood sera from the LPS group. At the end of the ex-
periment we found not only further increase in IL-6
levels but also increase in TNFα levels in both groups.
The levels of both TNFα and IL-6 were significantly
higher in LPS-treated group compared to control group.
TNFα is directly produced by macrophages in response
to LPS stimulation [36] and is also a typical marker for
AS in man [37]. The anti-TNF monoclonal antibodies
that act by neutralizing TNF have proved highly effective
in AS therapy, but also in the treatment of other spon-
dyloarthropathies [38,39].Conclusions
According to our results we conclude:
1. Repeated systemic stimulation with the microbial
component LPS caused an activation of the innate
immune system followed by suppression of both
arms of the immune system in the LPS-treated
males. These changes correlated with the reduction
of the ANKENT incidence.
2. Considerable increase in the anti-inflammatory IL-
10 level in the LPS-treated males can be a potential
mechanism that decreased the ANKENT incidence.
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development, expansion and function of the immune
system so that LPS-treated males were less
susceptible to ANKENT development than LPS-
untreated controls.
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